2022 TOS Summit (夏4冬2)

By /

2022/07/10 (Sun) ⬅️ (第一場 Breast Cancer, Precision Medicine)

  1. 09:00–09:10 Opening 中國醫大附設醫院癌症中心 邱昌芳院長
  2. 09:10–09:45 Tumor-agnostic treatment and comprehensive genomic profiling: What’s new in ASCO? (台大癌醫中心 高祥豐醫師)
    • Tumor-agnostic therapy: a type of therapy that uses drugs or other substances to treat cancer based on the cancer’s genetic and molecular features without regard to the cancer type or where the cancer started in the body. Tumor-agnostic therapy uses the same drug to treat all cancer types that have the genetic mutation (change) or biomarker that is targeted by the drug. It is a type of targeted therapy. Also called tissue-agnostic therapy.
  3. 09:45–10:20 How comprehensive is comprehensive genomic profiling (CGP): gene number, coverage, sample type, operation, and data ownership (北榮 黃其晟醫師)
  4. 10:35–11:20 Major advances of 2022 ASCO Meeting: Breast Cancer–1 (北榮趙大中醫師)
  5. 11:20–11:55 The evolving treatment of HR+HER2– advanced breast cancer: maximizing benefits for patient (北榮 賴峻毅醫師)
  6. 13:00–13:35 Re-defining the classification and treatment of HER2-expressing metastatic breast cancer (北榮劉峻宇醫師)
  7. 13:35–14:10 The changing treatment landscape for HR+ HER2– m8C patients with CDK4/6i (台大醫院黃柏翔醫師)
  8. 14:20–14:55 Reducing the risk of recurrence in HR+, HER2– EBC (台大醫院張瑞瑩醫師)
  9. 14:55–15:40 Major advances of 2022 ASCO meeting: Breast cancer-2 (台大醫院陳偉武醫師)
  10. 15:40–16:00 Panel discussion and closing (三軍總醫院 余志誠教授)

2022/07/16 (Sat) ⬅️ (第二場 GI)

  1. 09:00–09:10 Opening (高醫附設中和醫院 陳立宗教授)
  2. 09:10–09:55 Major advances of 2022 ASCO meeting: non-colorectal GI cancers (高醫附設中和醫院 白禮源醫師)
  3. 09:55–10:30 Gastrointestinal stromal tumor – recent progress and upcoming challenges in a diverse disease (高雄長庚 陳彥仰主任)
  4. 10:45–11:20 Current status and future perspective of immunotherapy in esophageal cancers (台大醫院 郭哲銓醫師)
  5. 11:20–11:55 Treatment outcome of targeted therapy IDH1 inhibitor for IDH1-mutated cholangiocarcinoma (台大癌醫 林宗哲醫師)
  6. 11:55–12:10 Panel discussion (北榮趙毅部主任)
  7. 13:00–13:45 Major advances of 2022 ASCO meeting: colorectal cancer (臺大醫院 梁逸歆醫師)
  8. 13:45–14:20 How to refine anti-EGFR treatment in mCRC patients (雙和醫院 謝ㄕㄠˋ燿宇醫師)
  9. 14:30–15:05 Major advances of mCRC treatment (和信醫院 黃國埕醫師)
  10. 15:05–15:40 Novel therapeutic strategies of colorectal cancer treatment (長庚醫院 徐鴻智醫師)
  11. 15:40–16:00 Panel discussion and closing (台大醫院 葉坤輝教授)

2022/07/17 (Sun) ⬅️ (第三場 新藥、H&C、GU)

  1. 09:00–09:10 Opening (楊志新理事長)
  2. 09:10–09:55 Major advances of 2022 ASCO meeting: Experimental therapeutics & new drug development (台大醫院林家齊教授)
  3. 09:55–10:30 Major advances of 2022 ASCO meeting: New drug development in sarcoma and others (台大醫院 陳偉武醫師)
  4. 10:45–11:20 Targeting FGFR in solid tumor: current status and emerging opportunities (中國附醫 葉士芃ㄆㄥˊ醫師)
  5. 11:20–12:05 Major advances of 2022 ASCO meeting: Head and neck cancer (台大癌醫中心 高祥豐醫師)
  6. 13:00–13:45 Major advances of 2022 ASCO meeting: GU cancer (林口長庚 蘇柏榮醫師)
  7. 13:45–14:20 Optimizing frontline treatment with immunotherapy in advanced/metastatic UC (台大醫院 蘇文彬教授)
  8. 14:30–15:05 From dark to clear era: what do we have CLARITY on ? (台大醫院 郭哲銓醫師)
  9. 15:05–15:40 New treatment landscape of immunotherapy in advanced GU cancer (北榮 張牧新醫師)
  10. 15:40–16:00 Panel discussion and closing (國防醫學院 查岱龍醫師)

2022/07/24 (Sun) ⬅️ (第四場 肺癌 Lung Cancer)

  1. 09:00–09:10 Opening (成大醫院 蘇五洲教授)
  2. 09:10–09:55 Major advances of 2022 ASCO meeting: Lung cancer (台北醫大 台北癌症中心 邱昭華醫師)
  3. 09:55–10:30
  4. 10:45–11:20 Navigating first-line treatment decisions to optimize outcomes for EGFRm+ NSCLC: from clinical evidences to real world excellence (林口長庚 吳教恩醫師)
  5. 11:20–12:05 Precision medicine therapy in RET fustion-positive NSCLC patients: from trial to practice (北榮 黃煦晴醫師)
  6. 11:55–12:30 From metastatic stage to resectable NSCLC: the crucial role of immunotherapy (台大醫院 廖唯昱醫師)
  7. 13:10–13:45 Optimal strategy for the treatment of ALK+ NSCLC (台大醫院 徐偉勛教授)
  8. 13:45–14:20 Evolving treatment option and practice in EGFR – mutant NSCLC (台大醫院 吳尚俊醫師)
  9. 14:30–15:05 Advancement in MET TKi for treating non-small cell lung cancer patients (台大醫院 廖唯昱醫師)
  10. 15:05–15:40 Brining evidences to tackle ALK+ NSCLC– what’s new for Brigatinib in 2022? (中國醫大附設醫院 夏德樁副主任)
  11. 15:40–16:00 Panel discussion and closing (楊志新理事長)

2022/10/22 (Sat) ⬅️ (第一天 Updates on EMSO)

  • 09:00–09:10 Opening (北榮 曾令民主任)
  • 09:10–09:45 Evolving perspectives: progress in the treatment of HR+ HER– advanced breast cancer (台大醫院黃柏翔醫師)
  • 09:45–10:20 Striving for significant survival benefit for the broadest set of patients in HR+HER2–mBC with CDK4/6i (嘉義長庚 官鋒澤醫師)
  • 10:35–11:10 The latest development of anti-HER2 antibody-drug conjugate in metastatic breast cancer (奇美醫院 郭雨萱醫師)
  • 11:10–11:45 Recent updates in HR+/HER2– breast cancer and future perspectives (成大醫院 鍾為邦醫師)
  • 11:45–12:20 Emerging treatment strategies for RCC: from adjuvant therapy to metastatic disease (北榮 張牧新醫師)
  • 13:00–13:35 New treatment landscape of immunotherapy in GU cancer from locally advanced stage to metastatic stage (台大醫院 郭哲銓醫師)
  • 13:35–14:10 The development of antibody-drug conjegates from later-line to expand the opportunity in frontline settings of la/mUC (台大醫院 蔡育傑醫師)
  • 14:10–14:45 Recent updated treatment strategies of prostate cancer: what we learned in 2022 (台大醫院 薛富仁醫師)
  • 14:55–15:30 The role of radioligand therapy in metastatic prostate cancer, now and in the future (林口長庚 蘇柏榮醫師)
  • 15:30–16:05 updates on treatments targeting FGFR fusions in cholangiocarcinoma (台大癌醫中心 莊建淮醫師)
    • 受ALC醫師看重
    • Annual New Cases of Liver Cancers in Taiwan (HCC/BTC)
    • Timeline of developments in systemic therapy of BTC
    • mIDH1 cholangiocarcinoma as a second-line or later-line therapy
  • 16:05–16:40 Clinical data update for advanced HCC treatment from 2022EMSO (北榮 洪逸平醫師)
  • 16:40–16:50 Closing (北榮 黃怡翔教授)

2022/10/23 (Sun) ⬅️ (第二天 Updates on EMSO)

  • 09:00–09:10 Opening (楊志新理事長)
  • 09:10–09:45 The update of personalized healthcare in oncology (土城長庚醫院 謝佳訓醫師)
    • 2022進展CUP (cancer of unknown primary)
    • EMSO recommends use of genomic testing: 2018 – NSCLC – 2019 – Thyroid cancer – 2020 – prostate cancer, cholangiocarcinoma, ovarian cancer, CRC, CUP – 2021 – GIST, breast cancer, bladder cancer, – 2022 – endometrial cancer
    • US NCCN guidelines – rapid uptake of genomic testing indications (including HNC). ASCO recommends patients with advanced or metastatic cancer should undergo genomic sequencing using multigene panel based assays if more than one biomarker-linked therapy is approved in the patient’s disease.
    • The drug rediscovery protocol (DRUP): an adaptive precision oncology trial
      • In the first 500 patients treated in DRUP. 33% overall clinical benefit rate
    • TAPISTRY: tumor agnostic precision immuno-oncology and somatic targeting rational for you
      • beta.clinicaltrials.gov/study/NCT04589845 (Roche supported, 台灣有參賽)
      • Taiwan is included (NCKUH, TPEVGH, CGMH, NTUH)
      • Enrolment via local NGS testing (tissue only) –> CGP (tissue and liquid) used centrally for confirmation –> presence of biomarker confirmed
      • Biomarkers: ROS1 fusion, NTRK1/2/3 fusion, ALK fusion, PIK3CA double mutation, AKT1/2/3 mutation, HER2 mutation, TMB-high, BRAF class II/III mutation or fusion, RET fusion
  • 09:45–10:20 2022 NGS CGP precision medicine evolution and EMSPO updates (臺大醫院 梁逸歆醫師)
  • 10:35–11:10 Targeting p53 in solid tumor: current status and emerging opportunities (林口長庚 吳教恩醫師)
  • 11:10–11:45 Updated strategy and evidence for font-lint TKI treatment in advanced EGFR-mutant NSCLC (台大雲林分院 魯維丞醫師)
  • 11:45–12:20 Current treatment options and emerging opportunities of METi in NSCLC (高醫大附設中和醫院 楊志仁醫師)
  • 13:00–13:35 Clinical data update of Larotrectinib in NTRK fusion population (新竹台大醫院 李日翔)
  • 13:35–14:10 ESMO 2022 update–optimal sequential treatment for ALK+ NSCLC (成大醫院 林建中醫師)
  • 14:10–14:45 Expanding horizons for the targeted management of EGFR-mutatnt NSCLC (雙和醫院 李岡遠醫師)
  • 14:55–15:30 The crucial backbone of immunotherapy in treatment with NSCLC from resected to metastatic stage (成大醫院 蘇柏嵐醫師)
  • 15:30–16:05 The new evidence of MET inhibitors in lung cancer (新竹台大醫院 李日翔醫師)
  • 16:05–16:40 Unveiling the treatment potential of EGFR exon20ins+ NSCLC–Updates from WCLC and EMSO2022 (林口長庚吳教恩醫師)
    • 發現YCL’s case was done by PCR assay (Cobalt assay)
  • 16:05–16:40 Closing (林口長庚 張文震主任)
Scroll to Top